Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study.

ABSTRACT:

Background

 Selective serotonin reuptake inhibitors (SSRIs) may increase the risk of major bleeding by decreasing platelet function or decreasing vitamin K antagonist (VKA) metabolism via cytochrome P450 (CYP) inhibition.

Aims

 To determine whether SSRIs are associated with major bleeding during VKA treatment and investigate the possible mechanisms.

Methods

 In this cohort study, information on SSRI use and bleeding complications was obtained from patient records of VKA initiators between 2006 and 2018 from two anticoagulation clinics. Conditional logistic regression and time-dependent Cox regression were used to estimate the effect of SSRIs on a high international normalized ratio (INR ≥ 5) within 2 months after SSRI initiation and on major bleeding during the entire

SUBMITTER: Bakker S 

PROVIDER: S-EPMC9904966 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature